Management of overweight and obesity in patients with cardiovascular disease

British Journal of Cardiology

Volumn 9, Issue 1, 2002, Pages 42-46

  Schachter, Michael ^a   Purcell, Henry ^a   Daly, Caroline ^a   Sheppard, Mary ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti obesity drugs; Cardiovascular disease; Obesity; Orlistat; Overweight; Sibutramine; Surgical management

Indexed keywords

ACARBOSE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; CALCIUM ANTAGONIST; CHORIONIC GONADOTROPIN; DEXAMPHETAMINE; DEXFENFLURAMINE; DIGOXIN; DIURETIC AGENT; DOPAMINE UPTAKE INHIBITOR; EPHEDRINE; FEN PHEN; FENFLURAMINE; FLUOXETINE; METFORMIN; NORADRENALIN UPTAKE INHIBITOR; PHENTERMINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; THYROXINE; UNCLASSIFIED DRUG; VENLAFAXINE; WARFARIN;

ANXIETY NEUROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG POTENCY; DRUG RELEASE; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PUBLIC HEALTH; REVIEW; RISK FACTOR; SITTING; UNITED KINGDOM; VASCULARIZATION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0036160399     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Impairment of health and quality of life in people with large waist circumference
2. Coronary heart disease statistics
3. Obesity. Impact on cardiovascular disease
4. Body-mass index and mortality in a prospective cohort of US adults
5. Obesity, Cinderella of CHD risk factors
6. Relation of weight changes to changes in atherogenic traits: The Framingham Study
7. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study
8. Overweight and obesity: A major challenge for coronary heart disease secondary prevention in clinical practice in Europe
9. Elevated C-reactive protein levels in overweight and obese adults
10. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries
11. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss
12. Heart rate variability in obesity and the effect of weight loss
13. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity
14. Weight control practices of US adults trying to lose weight
15. Prevalence of attempting weight loss and strategies for controlling weight
16. Metabolic effects of high-protein, low carbohydrate diets
17. Dietary protein and weight reduction
18. Changing behaviour
19. Weight reduction in a blood pressure clinic
20. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients
21. A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure
22. Long-term pharmacotherapy in the management of obesity
23. Pharmacological approaches. Ch10
24. Valvular heart disease associated with fenfluramine-phentermine
25. Long-term pharmacotherapy of obesity 2000. A review of efficacy and safety
26. Orlistat: A new agent for the treatment of obesity
27. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
28. Treatment with orlistat reduces cardiovascular risk in obese patients
29. The effect of orlistat on bodyweight and coronary heart disease risk profile in obese patients; The Swedish Multimorbidity study
30. Sibutramine: A new drug in the treatment of obesity
31. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
32. Efficacy and safety of sibutramine in obese White and African American patients with hypertension
33. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
34. The prevention and treatment of obesity
35. Obesity surgery grows in popularity in the US
36. The effect of obesity on long-term survival following coronary bypass